Pharmacodynamic and pharmacokinetic properties of enoxaparin: Implications for clinical practice

Clinical Pharmacokinetics

Volumn 42, Issue 12, 2003, Pages 1043-1057

  Fareed, Jawed ^a   Hoppensteadt, Debra ^a   Walenga, Jeanine ^a   Iqbal, Omer ^a   Ma, Qing ^a   Jeske, Walter ^a   Sheikh, Taqdees ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARDEPARIN; DALTEPARIN; ENOXAPARIN; PARNAPARIN; TINZAPARIN; TISSUE FACTOR PATHWAY INHIBITOR;

AGE DISTRIBUTION; BIOSAFETY; BLOOD CLOTTING; DOSE RESPONSE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INTOXICATION; DRUG METABOLISM; DRUG TARGETING; HUMAN; KIDNEY FAILURE; LONG TERM CARE; MOLECULAR INTERACTION; NONHUMAN; OBESITY; OSTEOPOROSIS; PREGNANCY; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; THROMBOCYTE;

AGE FACTORS; ANTICOAGULANTS; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS; ENOXAPARIN; FEMALE; HALF-LIFE; HUMANS; KIDNEY FAILURE; OBESITY; PREGNANCY;

EID: 0141650359     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200342120-00003     Document Type: Review

References (81)

1. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114 (5 Suppl.): 489S-510S
2. Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis 1996; 26 Suppl. 2: 24-38
3. Kandrotas RJ. Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinetics 1992; 22 (5): 359-74
4. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91
5. Walker AM, Jick H. Predictors of bleeding during heparin therapy. JAMA 1980; 244: 1209-12
6. Ginsberg JS, Kowalchuk G, Hirsh J, et al. Heparin effect on bone density. Thromb Haemost 1990; 64: 286-9
7. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17
8. Fareed J, Jeske W, Hoppensteadt D, et al. Are all available low-molecular-weight heparin preparations the same? Semin Thromb Hemost 1996; 22 Suppl. 1: 77-91
9. Brieger D, Dawes J. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins. Thromb Haemost 1997; 77: 317-22
10. Cohen M, Demeers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease: efficacy and safety of subcutaneous enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337: 447-52
11. Fareed J, Walenga JM, Hoppensteadt D, et al. Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins. Haemostasis 1988; 18 Suppl. 3: 3-15
12. Padilla A, Gray E, Pepper DS, et al. Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4). Br J Haematol 1992; 82: 406-13
13. Fareed J, Walenga JM, Hoppensteadt D, et al. Biochemical and pharmacologic inequivalence of low molecular weight heparins. Ann N Y Acad Sci 1989; 556: 333-53
14. Béguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemost 1988; 60: 457-62
15. Bara L, Bloch MF, Zitoun D, et al. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor. Thromb Res 1993; 69: 443-52
16. Matthiasson SE, Lindblad B, Stjernquist U, et al. The haemorrhagic effect of low molecular weight heparins, dermatan sulphate and hirudin. Haemostasis 1995; 25: 203-11
17. Bang CJ, Berstad A, Talstad I. Haemorrhagic effects of unfractionated and two low molecular weight heparins, enoxaparin and fragmin, in rats. Haemostasis 1991; 21: 30-6
18. Bendz B, Hansen J-B, Andersen TO, et al. Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins. Br J Haematol 1999; 107: 756-62
19. Hansen J-B, Sandset PM, Huseby KR, et al. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action. Br J Haematol 1998; 101: 638-46
20. Bendetowicz AV, Kai H, Knebel R, et al. The effect of subcutaneous injection of unfractionated and low molecular weight heparin on thrombin generation in platelet rich plasma: a study in human volunteers. Thromb Haemost 1994; 72: 705-12
21. Schoen P, Lindhout T, Franssen J, et al. Low molecular weight heparin-catalyzed inactivation of factor Xa and thrombin by antithrombin III: effect of platelet factor 4. Thromb Haemost 1991; 66: 435-41
22. Beguin S, Mardiguian J, Lindhout T, et al. The mode of action of low molecular weight heparin preparation (PK10169) and two of its major components on thrombin generation in plasma. Thromb Haemost 1989; 61: 30-4
23. Messmore Jr HL, Griffin B, Fareed J, et al. In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets. Ann N Y Acad Sci 1989; 556: 217-32
24. Cade JF, Buchanan MR, Boneu B, et al. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb Res 1984; 35: 613-25
25. Brace LD, Fareed J, Tomeo J, et al. Biochemical and pharmacological studies on the interaction of PK 10160 and its subfractions with human platelets. Haemostasis 1986; 16: 93-105
26. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998; 97: 251-6
27. Fernandez F, N'guyen P, Van Ryn J, et al. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res 1986; 43: 491-5
28. Mirshahi M, Soria J, Neuhart E, et al. Effect of heparin and enoxaparin on platelet interaction with fibrin clots. Thromb Res 1992; 65: 187-91
29. Van Rijn JLML, Trillou M, Mardiguian T, et al. Selective binding of heparins to human endothelial cells: implications for pharmacokinetics. Thromb Res 1987; 45: 211-22
30. Zammit A, Pepper DS, Dawes J. Interaction of immobilised unfractionated and LMW heparins with proteins in whole human plasma. Thromb Haemost 1993; 70: 951-8
31. Young E, Cosmi B, Weitz J, et al. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (enoxaparin) to plasma proteins. Thromb Haemost 1993; 70: 625-30
32. Young E, Wells P, Holloway S, et al. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994; 71: 300-4
33. Bhandari M, Hirsh J, Weitz JI, et al. The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb Haemost 1998; 80: 413-7
34. Fareed J, Walenga JM, Hoppensteadt DA, et al. Laboratory studies on the intravenous and subcutaneous administration of PK 10169 in man. Haemostasis 1986; 16: 123-38
35. Montalescot G, Philippe F, Ankri A, et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation 1998; 98: 294-9
36. Hodl R, Hubert K, Kraxner W, et al. Comparison of effects of dalteparin and enoxaparin on hemostatic parameters and von Willebrand factor in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. Am J Cardiol 2002; 89 (5): 589-92
37. Montalescot G, Collet JP, Lison L, et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000; 36 (1): 110-4
38. Cornelli U, Fareed J. Human pharmacokinetics of low molecular weight heparins. Semin Thromb Hemost 1999; 25 Suppl. 3: 57-61
39. Dawes J. Comparison of the pharmacokinetics of enoxaparin (Clexane®) and unfractionated heparin. Acta Chir Scand 1990; 156 (556 Suppl.): 68-74
40. Azizi M, Veyssier-Belot C, Alhenc-Gelas M, et al. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers. Br J Clin Pharmacol 1995; 40: 577-84
41. Collignon F, Frydman A, Caplain H, et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins: dalteparin, enoxaparin and nadroparin: administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995; 73: 630-40
42. Eriksson BI, Soderberg K, Widlund L, et al. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost 1995; 73: 398-401
43. Frydman AM, Bara L, Le Roux Y, et al. The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80mg. J Clin Pharmacol 1988; 28: 609-18
44. Bara L, Billaud E, Gramond G, et al. Comparative pharmacokinetics of a low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985; 39: 631-6
45. Samama MM, Gerotziafas GT. Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 2000; 26 Suppl. 1: 31-8
46. Bendetowicz AV, Beguin S, Caplain H, et al. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin: a three way cross over study in human volunteers. Thromb Haemost 1994; 71: 305-13
47. Rabah MM, Premmereur J, Graham M, et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999; 84: 1391-5
48. Laforest MD, Colas-Linhart N, Guiraud-Vitaux F, et al. Pharmacokinetics and biodistribution of technetium 99m labelled standard heparin and a low molecular weight heparin (enoxaparin) after intravenous injection in normal volunteers. Br J Haematol 1991; 77: 201-8
49. Bara L, Samama M. Pharmacokinetics of low molecular weight heparins. Acta Chir Scand Suppl 1988; 543: 65-72
50. Boneu B, Caranobe C, Sie P. Pharmacokinetics of heparin and low molecular weight heparin. Baillieres Clin Haematol 1990; 3: 531-44
51. Cadroy Y, Pourrat J, Baladre MF, et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res 1991; 63: 385-90
52. Eldor A. Thrombophilia, thrombosis and pregnancy. Thromb Haemost 2001; 86 (1): 104-11
53. Sanson BJ, Lensing AW, Prins MH, et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81: 668-72
54. Casele HL, Laifer SA, Woelkers DA, et al. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999; 181 (5 Pt 1): 1113-7
55. Gibson JL, Ekevall K, Walker I, et al. Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. Br J Obstet Gynaecol 1998; 105: 795-7
56. Forestier F, Daffos F, Capella-Pavlovsky M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound. Thromb Res 1984; 34: 557-60
57. Arcavi L, Maier A, Caspi A. Safety of enoxaparin in the geriatric population [abstract]. Eur Heart J 1999; 20 Suppl. 1: 285
58. Massicotte P, Adams M, Marzinotto V, et al. Low-molecular weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996; 128: 313-8
59. Punzalen RC, Hillery CA, Montgomery RR, et al. Low-molecular-weight heparin in thrombotic disease in children and adolescents. J Pediatr Hematol Oncol 2000; 22 (2): 137-4
60. Sanderink G, LeLiboux A, Jariwala N, et al. Enoxaparin pharmacokinetics and pharmacodynamics in renal impairment [abstract]. J Am Coll Cardiol 2001; 37 (2) Suppl. A: 229A
61. Bruno R, Vivier N, Veyrat-Follet C, et al. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Invest New Drugs 2001; 19: 163-9
62. Busby LT, Weyman A, Rodgers GM. Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin. Am J Hematol 2001; 67 (1): 54-6
63. Gerlach AT, Pickworth KK, Seth SK, et al. Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 2000; 20 (7): 771-5
64. Inverso SM, Cohen M, Antman EM, et al. Safety and efficacy of unfractionated heparin versus enoxaparin in obese patients and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies [abstract]. J Am Coll Cardiol 2001; 37 (2) Suppl. A: 365A
65. Follea G, Laville M, Pozet N, et al. Pharmacokinetic studies of standard heparin and low molecular weight heparin in patients with chromic renal failure. Haemostasis 1986; 16: 147-51
66. Brophy DF, Wazny LD, Gehr TW, et al. The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease. Pharmacotherapy 2001; 21 (2): 169-74
67. Przedlacki J, Bogdanska-Straszynska B, Sawicka B, et al. Antithrombotic activity of low molecular weight heparin (enoxaparin) during hemodialysis in patients with terminal kidney failure [in Polish]. Pol Arch Med Wewn 1993; 91: 438-45
68. Sanderink G, LeLiboux A, Jariwala N, et al. Enoxaparin pharmacokinetics and pharmacodynamics in obese [abstract]. J Am Coll Cardiol 2001; 37 (2) Suppl. A: 229A
69. Cipolle RJ, Seifert RD, Neilan BA, et al. Heparin kinetics: variables related to disposition and dosage. Clin Pharmacol Ther 1981; 29: 387-93
70. Goodman SG, Cohen M, Bigonzi F, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE study: efficacy and safety of subcutaneous enoxaparin in non-Q wave coronary events. J Am Coll Cardiol 2000; 36 (3): 693-8
71. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) IIB trial. Circulation 1999; 100: 1593-601
72. The FRAX. I.S. Study Group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. Eur Heart J 1999; 20: 1553-62
73. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999; 354: 701-7
74. Michalis LK, Papamichail N, Katsouras CS, et al. Enoxaparin versus tinzaparin in the management of unstable coronary artery disease (EVET Study) [abstract]. J Am Coll Cardiol 2001; 37 (2): 365A
75. Zidar JP. Low-molecular-weight heparins in coronary stenting (the ENTICES trial): ENoxaparin and TIClopidine after Elective Stenting. Am J Cardiol 1998; 82: 29L-32L
76. Kereiakes DJ, Young J, Broderick TM, et al. Therapeutic adjuncts for immediate transfer to the catheterization laboratory in patients with acute coronary syndromes. Am J Cardiol 2000; 86 Suppl. 12B: 10M-7M
77. Young JJ, Kereiakes DJ, Grines CL, et al. Low-molecular weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 Trials. J Invasive Cardiol 2000; 12 Suppl. E: E14-8
78. Kereiakes DJ, Grines C, Fry E, et al. National investigators collaborating on enoxaparin: enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 2001; 13 (4): 272-8
79. Planes A, Vochelle N, Mazas F, et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 1988; 60: 407-10
80. The German Hip Arthroplasty Trial (GHAT) Group. Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement: a randomized trial. Arch Orthop Trauma Surg 1992; 111 (2): 110-20
81. Nightingale SL. From the food and drug administration [letter]. JAMA 1993; 270: 1672